Obesity Medicine , 48, 100545
Despite promising results from existing randomized controlled trials of semaglutide and tirzepatide in those with obesity-related HFpEF, regulatory authorities and professional societies have not approved or endorsed the use of these drugs for HFpEF, due in part to the studies relatively small sample sizes and unknown generalizability
Patients combining semaglutide injections with alcohol frequently report worsened GI symptoms that can persist for hours after drinking
Kurki MI, Karjalainen J, Palta P, Sipil TP, Kristiansson K, Donner KM, et al
Liraglutide attenuates myocardial ischemia/reperfusion injury through the inhibition of necroptosis by activating GLP-1R/PI3K/Akt pathway
Thats due in no small part to their effectiveness in contributing to significant weight loss